Hyundai Bioscience Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 1,963.12 million compared to KRW 2,382.94 million a year ago. Net loss was KRW 1,979.09 million compared to net income of KRW 3,355.67 million a year ago. Basic loss per share from continuing operations was KRW 50 compared to basic earnings per share from continuing operations of KRW 85 a year ago. Diluted loss per share from continuing operations was KRW 50 compared to diluted earnings per share from continuing operations of KRW 85 a year ago. Basic loss per share was KRW 50 compared to basic earnings per share of KRW 85 a year ago.
For the nine months, sales was KRW 124.96 million compared to KRW 90.29 million a year ago. Net loss was KRW 6,413.17 million compared to KRW 4,661.33 million a year ago. Basic loss per share from continuing operations was KRW 161 compared to KRW 119 a year ago. Diluted loss per share from continuing operations was KRW 161 compared to KRW 119 a year ago. Basic loss per share was KRW 161 compared to KRW 119 a year ago.